Copyright West LLC. Minimum 15 minutes delayed.

Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dicerna Pharmaceuticals Announces New Data That Show Dicer-substrate RNA Molecules Produce More Potent, Longer Lasting Gene Silencing Than Shorter siRNA Molecules; Results Published in Journal of Biomolecular Techniques View HTML
Toggle Summary Dicerna Co-Founder and Scientific Advisory Board Chair Present at American Association of Pharmaceutical Scientists 2008 Meeting Exposition View HTML
Toggle Summary Dicerna Pharmaceuticals, an RNA Interference Company, to Present at Discovery on Target Conference View HTML
Toggle Summary Dicerna Pharmaceuticals to Present at First Annual Boston Biotech R&D Conference View HTML
Toggle Summary Dicerna Pharmaceuticals Appoints Leading Experts to Scientific Advisory Board View HTML
Toggle Summary Dicerna Pharmaceuticals Announces Preclinical Findings Highlighting Novel Approach to Maximizing Dicer-Substrate Small Interfering RNAs (DsiRNAs) in Rheumatoid Arthritis; Data Appear Published by Molecular Therapy View HTML
Toggle Summary Dicerna Pharmaceuticals, a Second Generation RNA Interference Company, Completes Second Closing of Series A Financing; Unveils Strategic Focus View HTML
Toggle Summary Dicerna Pharmaceuticals, a RNA Interference Company, to Present at 9th Annual Beyond Genome Conference View HTML
Toggle Summary Dicerna Pharmaceuticals Appoints C. Ronald Kahn, M.D., Vice Chairman of Joslin Diabetes Center, to its Scientific Advisory Board View HTML
Toggle Summary Dicerna, Startup Based on RNAi Biology, Licenses IP from City of Hope and Closes $13 Million Series A Financing View HTML